Review



recombinant mouse fgf4  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems recombinant mouse fgf4
    Recombinant Mouse Fgf4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 31 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/Recombinant+Mouse+FGF-4+Protein/pm25533345-192-0-5
    Average 93 stars, based on 31 article reviews
    recombinant mouse fgf4 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Regulation of lung cancer initiation and progression by the stem cell determinant Musashi
    Article Snippet: .. After sorting, cells were resuspended in full media [1X DMEM:F12 (Fisher Scientific) supplemented with 10%FBS, 1X pen/strep (Fisher Scientific), 1X N-2 supplement (Life Technologies), 35ug/mL bovine pituitary extract (Fisher Scientific), 20ng/mL recombinant mouse EGF (Biolegend), 20ng/mL recombinant mouse FGF (R&D Systems)]. .. Resuspended cells were mixed with an equal volume of growth factor reduced Matrigel (Corning) for a total volume of 100μL, plated in 96 well flat-bottom plates (Fisher Scientific) at a density of 500 cells/well.

    Article Title: Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma
    Article Snippet: .. Recombinant FGF proteins [mouse: FGF1, 4686-FA-025/CF (R&D Systems), FGF2, 3139-FB (R&D Systems), FGF4, 5846-F4 (R&D Systems), and FGF18, NBP2-35028 (Novus); human: FGF1, 233FB025CF (R&D Systems), FGF2, 232FA025CF (R&D Systems), FGF4, 7460F4025CF (R&D Systems), and FGF18, 8988F18050 (R&D Systems)] were resuspended in sterile-filtered PBS and used in vitro, where indicated, with heparin sulfate (1 μg/ml), as previously described ( 136 ). .. Human and murine chemokine, cytokine, and human FGF1 and FGF2 were assayed by Luminex technology using Bio-Plex Pro (Bio-Rad Laboratories) according to the manufacturer’s instructions.

    Article Title: Regulation of lung cancer initiation and progression by the stem cell determinant Musashi
    Article Snippet: .. Mouse primary lung cancer cell lines were established from end-stage KP f/f mice as follows: tumors were isolated and dissociated into single cell suspensions in the manner described above, then plated in 1X DMEM:F12 (Fisher Scientific) supplemented with 10%FBS, 1X pen/strep (Fisher Scientific), 1X N-2 supplement (Life Technologies), 35ug/mL bovine pituitary extract (Fisher Scientific), 20ng/mL recombinant mouse EGF (Biolegend), 20ng/mL recombinant mouse FGF (R&D Systems). .. Upon reaching 80% confluency the cells were collected and resuspended in HBSS (Gibco, Life Technologies) containing 5% FBS and 2mM EDTA, treated with FC block, and stained with EpCAM-APC (eBioscience), and CD31-PE (eBioscience).

    Sterility:

    Article Title: Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma
    Article Snippet: .. Recombinant FGF proteins [mouse: FGF1, 4686-FA-025/CF (R&D Systems), FGF2, 3139-FB (R&D Systems), FGF4, 5846-F4 (R&D Systems), and FGF18, NBP2-35028 (Novus); human: FGF1, 233FB025CF (R&D Systems), FGF2, 232FA025CF (R&D Systems), FGF4, 7460F4025CF (R&D Systems), and FGF18, 8988F18050 (R&D Systems)] were resuspended in sterile-filtered PBS and used in vitro, where indicated, with heparin sulfate (1 μg/ml), as previously described ( 136 ). .. Human and murine chemokine, cytokine, and human FGF1 and FGF2 were assayed by Luminex technology using Bio-Plex Pro (Bio-Rad Laboratories) according to the manufacturer’s instructions.

    In Vitro:

    Article Title: Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma
    Article Snippet: .. Recombinant FGF proteins [mouse: FGF1, 4686-FA-025/CF (R&D Systems), FGF2, 3139-FB (R&D Systems), FGF4, 5846-F4 (R&D Systems), and FGF18, NBP2-35028 (Novus); human: FGF1, 233FB025CF (R&D Systems), FGF2, 232FA025CF (R&D Systems), FGF4, 7460F4025CF (R&D Systems), and FGF18, 8988F18050 (R&D Systems)] were resuspended in sterile-filtered PBS and used in vitro, where indicated, with heparin sulfate (1 μg/ml), as previously described ( 136 ). .. Human and murine chemokine, cytokine, and human FGF1 and FGF2 were assayed by Luminex technology using Bio-Plex Pro (Bio-Rad Laboratories) according to the manufacturer’s instructions.

    Cell Culture:

    Article Title: Self-Organization of Mouse Stem Cells into an Extended Potential Blastoid
    Article Snippet: LCDM supplementation was added as indicated at the following concentrations: 10 ng ml −1 recombinant human LIF (L, 10 ng ml −1 ; Peprotech, 300–05), CHIR99021 (C, 3 mM; Stem Cell Institute, Cambridge, UK), (S)-(+)-Dimethindenemaleate (D, 2 mM; Tocris, 1425) and Minocycline hydrochloride (M, 2 mM; Santa Cruz Biotechnology, sc-203339). .. TSCs were were cultured on mitotically inactivated CF1 mouse embryonic fibroblasts (MEFs) in TSF4H medium with RPMI 1640 (Sigma, M3817) containing 20% FBS, 2 mM L-glutamine, 0.1 m-M2-ME, 1 mM sodium pyruvate, and 1% penicillin-streptomycin, plus FGF4 (25 ng/mL; R&D Systems, 5846-F4) and heparin (1 μg ml −1 ; Sigma, H3149). . .. Cell Lines Experiments were performed using mouse Pdgfra ESCs or EPSCs ( Hamilton et al., 2003 ), CAG:GFP ESCs or EPSCs ( Rhee et al., 2006 ) ROSA-mTmG ESCs or EPSCs ( Muzumdar et al., 2007 ) (all derived in M.Zernicka-Goetz’s lab); wild-type TSCs (derived in M.Zernicka-Goetz’s lab) and EGFP TSCs.

    Article Title: Mechanism of paracrine communications between hepatic progenitor cells and endothelial cells.
    Article Snippet: .. After reaching 100% confluency, cells were washed with phosphate-buffered saline (PBS) twice and cultured in the hepatocytic differentiation medium consisting of Dulbecco’s Modified Eagle Medium (DMEM, 10569010, Gibco, MD, USA), 10% FBS (SH30090.03E, Hyclone Fisher, MA, USA), 100 unit/mL penicillin/streptomycin (15140122, Invitrogen, MA, USA), 2 mM L-glutamine (25030–081, Gibco, MD, USA), 1× nonessential amino acid solution (11140–050, Invitrogen, MA, USA), 100 nM dexamethasone (D1756, Sigma, MO, USA), 20% Matrigel (3524230, BD Biosciences, CA, USA), 20 μg/mL oncostatin M (495-MO, R&D system, MN, USA), 10 μg/mL HGF (100–39, Peprotech, NJ, USA), and 10 μg/mL fibroblast growth factor 4 (FGF4, 5846-F4, R&D Systems, MN, USA) [17]. .. For overexpression experiments, lentiviral vectors expressing mouse hepatocyte nuclear factor 4 alpha (Hnf4α, NM_008261) (LV528762, Applied Biological Materials, Richmond, Canada) and red fluorescent protein (RFP) (LV084, Applied Biological Materials, Richmond, Canada) under the control of the cytomegalovirus promoter were used for viral packaging and transduction of HPCs per the manufacturer’s protocol.

    Isolation:

    Article Title: Regulation of lung cancer initiation and progression by the stem cell determinant Musashi
    Article Snippet: .. Mouse primary lung cancer cell lines were established from end-stage KP f/f mice as follows: tumors were isolated and dissociated into single cell suspensions in the manner described above, then plated in 1X DMEM:F12 (Fisher Scientific) supplemented with 10%FBS, 1X pen/strep (Fisher Scientific), 1X N-2 supplement (Life Technologies), 35ug/mL bovine pituitary extract (Fisher Scientific), 20ng/mL recombinant mouse EGF (Biolegend), 20ng/mL recombinant mouse FGF (R&D Systems). .. Upon reaching 80% confluency the cells were collected and resuspended in HBSS (Gibco, Life Technologies) containing 5% FBS and 2mM EDTA, treated with FC block, and stained with EpCAM-APC (eBioscience), and CD31-PE (eBioscience).

    Single Cell:

    Article Title: Regulation of lung cancer initiation and progression by the stem cell determinant Musashi
    Article Snippet: .. Mouse primary lung cancer cell lines were established from end-stage KP f/f mice as follows: tumors were isolated and dissociated into single cell suspensions in the manner described above, then plated in 1X DMEM:F12 (Fisher Scientific) supplemented with 10%FBS, 1X pen/strep (Fisher Scientific), 1X N-2 supplement (Life Technologies), 35ug/mL bovine pituitary extract (Fisher Scientific), 20ng/mL recombinant mouse EGF (Biolegend), 20ng/mL recombinant mouse FGF (R&D Systems). .. Upon reaching 80% confluency the cells were collected and resuspended in HBSS (Gibco, Life Technologies) containing 5% FBS and 2mM EDTA, treated with FC block, and stained with EpCAM-APC (eBioscience), and CD31-PE (eBioscience).

    Saline:

    Article Title: Mechanism of paracrine communications between hepatic progenitor cells and endothelial cells.
    Article Snippet: .. After reaching 100% confluency, cells were washed with phosphate-buffered saline (PBS) twice and cultured in the hepatocytic differentiation medium consisting of Dulbecco’s Modified Eagle Medium (DMEM, 10569010, Gibco, MD, USA), 10% FBS (SH30090.03E, Hyclone Fisher, MA, USA), 100 unit/mL penicillin/streptomycin (15140122, Invitrogen, MA, USA), 2 mM L-glutamine (25030–081, Gibco, MD, USA), 1× nonessential amino acid solution (11140–050, Invitrogen, MA, USA), 100 nM dexamethasone (D1756, Sigma, MO, USA), 20% Matrigel (3524230, BD Biosciences, CA, USA), 20 μg/mL oncostatin M (495-MO, R&D system, MN, USA), 10 μg/mL HGF (100–39, Peprotech, NJ, USA), and 10 μg/mL fibroblast growth factor 4 (FGF4, 5846-F4, R&D Systems, MN, USA) [17]. .. For overexpression experiments, lentiviral vectors expressing mouse hepatocyte nuclear factor 4 alpha (Hnf4α, NM_008261) (LV528762, Applied Biological Materials, Richmond, Canada) and red fluorescent protein (RFP) (LV084, Applied Biological Materials, Richmond, Canada) under the control of the cytomegalovirus promoter were used for viral packaging and transduction of HPCs per the manufacturer’s protocol.

    Modification:

    Article Title: Mechanism of paracrine communications between hepatic progenitor cells and endothelial cells.
    Article Snippet: .. After reaching 100% confluency, cells were washed with phosphate-buffered saline (PBS) twice and cultured in the hepatocytic differentiation medium consisting of Dulbecco’s Modified Eagle Medium (DMEM, 10569010, Gibco, MD, USA), 10% FBS (SH30090.03E, Hyclone Fisher, MA, USA), 100 unit/mL penicillin/streptomycin (15140122, Invitrogen, MA, USA), 2 mM L-glutamine (25030–081, Gibco, MD, USA), 1× nonessential amino acid solution (11140–050, Invitrogen, MA, USA), 100 nM dexamethasone (D1756, Sigma, MO, USA), 20% Matrigel (3524230, BD Biosciences, CA, USA), 20 μg/mL oncostatin M (495-MO, R&D system, MN, USA), 10 μg/mL HGF (100–39, Peprotech, NJ, USA), and 10 μg/mL fibroblast growth factor 4 (FGF4, 5846-F4, R&D Systems, MN, USA) [17]. .. For overexpression experiments, lentiviral vectors expressing mouse hepatocyte nuclear factor 4 alpha (Hnf4α, NM_008261) (LV528762, Applied Biological Materials, Richmond, Canada) and red fluorescent protein (RFP) (LV084, Applied Biological Materials, Richmond, Canada) under the control of the cytomegalovirus promoter were used for viral packaging and transduction of HPCs per the manufacturer’s protocol.



    Similar Products

    96
    Bio-Rad rat anti mouse monoclonal f4 80
    Rat Anti Mouse Monoclonal F4 80, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/Rat+anti+Mouse+F4%2F80/10__22203_slash_ecm__v033a11-129-8-16
    Average 96 stars, based on 1 article reviews
    rat anti mouse monoclonal f4 80 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    98
    Cell Signaling Technology Inc anti f4 80
    Anti F4 80, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+XP+Rabbit+mAb/pmc13770902-39-29-30
    Average 98 stars, based on 1 article reviews
    anti f4 80 - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    96
    Proteintech f4 80
    F4 80, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+Antibody/pm42875944-344-6-7
    Average 96 stars, based on 1 article reviews
    f4 80 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    97
    Santa Cruz Biotechnology f4 80
    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
    F4 80, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+Antibody/pmc13748629-100-40-43
    Average 97 stars, based on 1 article reviews
    f4 80 - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    96
    Proteintech anti f4 80
    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
    Anti F4 80, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+Antibody/pm43004435-113-16-17
    Average 96 stars, based on 1 article reviews
    anti f4 80 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Proteintech tongue sections
    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
    Tongue Sections, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+Antibody/pm43002206-201-3-12
    Average 96 stars, based on 1 article reviews
    tongue sections - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Proteintech fitc conjugated anti f4 80 antibody
    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
    Fitc Conjugated Anti F4 80 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+Antibody/pm42985724-416-15-20
    Average 96 stars, based on 1 article reviews
    fitc conjugated anti f4 80 antibody - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    98
    Cell Signaling Technology Inc f4 80
    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
    F4 80, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/F4%2F80+XP+Rabbit+mAb/pm42988024-103-19-21
    Average 98 stars, based on 1 article reviews
    f4 80 - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    95
    Selleck Chemicals 10058 f4
    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
    10058 F4, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/f4/10058-F4/pm42980512-49-61-62
    Average 95 stars, based on 1 article reviews
    10058 f4 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b + F4/80 + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.

    Journal: Cancer Communications

    Article Title: Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies

    doi: 10.34133/cancomm.0065

    Figure Lengend Snippet: Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b + F4/80 + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.

    Article Snippet: Sections were incubated overnight at 4 °C with primary antibodies against CD8 (Cat. #ab217344, Abcam), CD3 (Cat. #ab135372, Abcam), NK1.1 (Cat. #ab289542, Abcam), CXCR3 (Cat. #ab288437, Abcam), C-X-C motif chemokine ligand 10 (CXCL10, Cat. #10937-1-AP, Proteintech), GZMB (Cat. #13588-1-AP, Proteintech), F4/80 (Cat. #sc-52664, Santa Cruz), and secreted phosphoprotein 1 (SPP1, Cat. #sc-21742, Santa Cruz).

    Techniques: Analysis, Control, Expressing, Marker, Protein-Protein interactions, Flow Cytometry, Tissue, Quantitative Proteomics, Multiplex Assay, Immunofluorescence, Single Cell, RNA Sequencing, Standard Deviation